Skip to main content
. 2019 Mar 1;133(5):645–663. doi: 10.1042/CS20180816

Figure 5. Changing FOXM1 expression influences the activity of NF-κB in cells treated with gemcitabine.

Figure 5

(A,B) Pancreatic cancer cells overexpressing or knocked out for FOXM1 were treated with gemcitabine, and the downstream proteins of NF-κB in the pancreatic cancer cells were detected using Western blotting analysis. (C,D) After the indicated treatments, the activities of the p65 subunit of NF-κB were further examined using a NF-κB dual luciferase reporter assay. Results shown are representative of three independent assays. *P<0.05; **P<0.01; ***P<0.001.